今日申购：北芯生命

Group 1 - The company, Shenzhen Beixin Life Technology Co., Ltd., focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [2] - The company is a national high-tech enterprise with a decentralized shareholding structure, where the actual controller, Song Liang, holds 16.1530% directly and controls a total of 29.5670% through employee stock ownership platforms [2] - The company plans to raise approximately 95.221 million yuan for the construction of an interventional medical device industrialization base, R&D projects, and to supplement working capital [2] Group 2 - The company is set to issue shares at a price of 17.52 yuan per share, with a total of 57 million new shares, aiming to raise approximately 99.864 million yuan, netting around 89.889 million yuan after deducting issuance costs [3] - The public offering is scheduled for January 26, 2026, with a maximum subscription limit of 9,000 shares for individual investors [1] - The company operates in the specialized equipment manufacturing industry, with a reference industry price-earnings ratio of 41.36 [1]